Sees FY26 Adjusted EBITDA of $73M-$77M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy HSTM?
Sees FY26 adjusted EBITDA $73M-$77M.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HSTM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HSTM
Wall Street analysts forecast HSTM stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 21.230
Low
25.00
Averages
25.00
High
25.00
Current: 21.230
Low
25.00
Averages
25.00
High
25.00
About HSTM
HealthStream, Inc. provides platform-delivered workforce solutions. Its solutions include Software-as-a-Service (SaaS), subscription-based applications used by healthcare organizations to meet a range of their workforce development needs around learning, clinical development, credentialing, and scheduling. Its content libraries allow customers to subscribe to an array of courseware, which includes content from healthcare and nursing associations, medical and healthcare publishers, and other content providers. Its scheduling solutions provide customers with real-time visibility into clinical staff scheduling. Its credentialing, privileging, and enrollment solution, CredentialStream, provides customers a user experience with a continual stream of enhancements, evidence-based content, and curated data, which provides healthcare organizations with tools to support the provider lifecycle management from recruiting, application submission, verification of licensure, and other credentials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HealthStream Reports Q4 2025 Earnings with Strong Growth and Strategic Acquisitions
- Significant Revenue Growth: HealthStream reported Q4 2025 revenues of $79.7 million, reflecting a 7.4% year-over-year increase, with subscription product revenues rising by $5.8 million, indicating strong market performance and heightened customer demand.
- Adjusted EBITDA Improvement: The adjusted EBITDA reached $18.8 million, up 16.4% year-over-year, despite operating income declining by 48.8% to $2.4 million, showcasing the company's solid profitability and effective cost management.
- Acquisitions and Share Buyback: The company completed two acquisitions in 2025, namely Virsys12 and MissionCare Collective, and initiated a $10 million share repurchase program in November, reflecting confidence in future growth and flexibility in capital allocation.
- Optimistic 2026 Outlook: Management projects 2026 revenues between $323 million and $330 million, with net income expected between $20.4 million and $22.8 million, indicating a positive outlook on market demand and a strategic plan for sustained growth.
See More
HealthStream Declares 12.9% Increase in Quarterly Dividend
- Dividend Increase: HealthStream declares a quarterly dividend of $0.035 per share, representing a 12.9% increase from the previous $0.031, indicating the company's commitment to stable cash flow and shareholder returns.
- Yield Metrics: The forward yield of 0.66% reflects the company's attractiveness to investors in the current market environment, aiming to bolster shareholder confidence and attract further investment.
- Earnings Beat: HealthStream reports a non-GAAP EPS of $0.18, beating expectations by $0.01, with revenue of $79.7 million exceeding forecasts by $3.49 million, showcasing the company's competitive edge and sustained profitability.
- Acquisition Strategy: HealthStream's acquisition of MissionCare Collective for up to $40 million aims to drive future growth by expanding service offerings and enhancing market share, further solidifying its position in the healthcare sector.
See More
HealthStream Q4 Earnings Beat Expectations with Strategic Acquisitions
- Strong Earnings Report: HealthStream reported a Q4 non-GAAP EPS of $0.18, beating expectations by $0.01, with revenue of $79.7 million reflecting a 7.4% year-over-year increase, surpassing estimates by $3.49 million, indicating robust market performance.
- Strategic Acquisitions: The company completed acquisitions of Virsys12 and MissionCare Collective for up to $40 million, aimed at enhancing service capabilities and competitive positioning through resource integration.
- Share Repurchase Program: HealthStream authorized a share repurchase program to buy back up to $10 million of common stock by November 11, 2025, having already repurchased $5 million in Q4, with another $5 million planned for January 2026, aimed at enhancing shareholder value.
- Full-Year Performance Overview: Total revenues for 2025 reached $304.1 million, up 4.3%, although operating income fell 4.9% to $20.2 million, primarily impacted by the CEO stock gift; excluding this, non-GAAP operating income was $24 million, reflecting a 12.8% increase, indicating improved profitability on an adjusted basis.
See More
HealthStream Reports Decline in Q4 Profit
- Profit Decline: HealthStream, Inc. reported a net profit of $2.53 million for Q4, translating to $0.09 per share, which is a significant drop from last year's $4.88 million and $0.16 per share, indicating pressure on the company's profitability.
- Adjusted Earnings: Excluding items, HealthStream's adjusted earnings stood at $5.35 million or $0.18 per share, showing some improvement in adjusted metrics, yet overall profitability remains below last year's levels.
- Revenue Growth: The company experienced a 7.4% year-over-year revenue increase, reaching $79.70 million compared to $74.23 million last year, suggesting some growth potential in its operations.
- Market Reaction: Despite revenue growth, the significant decline in profits may negatively impact investor confidence, leading to stock price volatility and reflecting market concerns regarding the company's future profitability.
See More
HealthStream Reports Q4 and Full-Year 2025 Financial Results
- Revenue Growth: HealthStream's Q4 2025 revenue reached $79.7 million, a 7.4% increase year-over-year, with subscription revenue rising by $5.8 million, indicating strong customer demand and reinforcing its market position in healthcare technology.
- Impact of CEO Stock Gift: The $3.8 million stock gift from CEO Frist led to a 48.8% decline in operating income to $2.4 million for Q4, but excluding this impact, non-GAAP operating income rose 31.7% to $6.2 million, showcasing the company's underlying growth potential.
- Annual Performance Review: For the full year 2025, revenues totaled $304.1 million, up 4.3%, although net income fell to $18.3 million; however, excluding the CEO stock gift's impact, non-GAAP net income increased by 5.8% to $21.2 million, reflecting effective cost control and efficiency improvements.
- Future Outlook: The company projects 2026 revenues between $323 million and $330 million, with net income expected to be between $20.4 million and $22.8 million, reflecting optimism about new sales and renewals while indicating HealthStream's pivotal role in the AI-driven healthcare landscape.
See More
Investment Opportunities in Oversold Healthcare Stocks
- Oversold Stocks Overview: The healthcare sector's oversold stocks present investors with opportunities to buy undervalued companies, particularly those with a Relative Strength Index (RSI) below 30, indicating potential short-term rebounds.
- Schrödinger Inc Performance: Schrödinger (NASDAQ:SDGR) has seen its stock price fall approximately 28% over the past month, currently holding an RSI of 29.9 and a 52-week low of $11.15, although shares rose 1.6% to $11.81 on Wednesday, indicating some rebound potential.
- Edge Stock Ratings: With a momentum score of 2.78, Schrödinger's performance is relatively weak in the market, yet its oversold status may attract investor interest, especially during market recoveries.
- Industry Dynamics Analysis: As the healthcare sector experiences volatility, investors should focus on the potential rebound opportunities of oversold stocks, particularly those with RSIs near or below 30, to capitalize on gains when the market stabilizes.
See More
HealthStream Reports Q4 2025 Earnings with Strong Growth and Strategic Acquisitions
- Significant Revenue Growth: HealthStream reported Q4 2025 revenues of $79.7 million, reflecting a 7.4% year-over-year increase, with subscription product revenues rising by $5.8 million, indicating strong market performance and heightened customer demand.
- Adjusted EBITDA Improvement: The adjusted EBITDA reached $18.8 million, up 16.4% year-over-year, despite operating income declining by 48.8% to $2.4 million, showcasing the company's solid profitability and effective cost management.
- Acquisitions and Share Buyback: The company completed two acquisitions in 2025, namely Virsys12 and MissionCare Collective, and initiated a $10 million share repurchase program in November, reflecting confidence in future growth and flexibility in capital allocation.
- Optimistic 2026 Outlook: Management projects 2026 revenues between $323 million and $330 million, with net income expected between $20.4 million and $22.8 million, indicating a positive outlook on market demand and a strategic plan for sustained growth.
See More
HealthStream Declares 12.9% Increase in Quarterly Dividend
- Dividend Increase: HealthStream declares a quarterly dividend of $0.035 per share, representing a 12.9% increase from the previous $0.031, indicating the company's commitment to stable cash flow and shareholder returns.
- Yield Metrics: The forward yield of 0.66% reflects the company's attractiveness to investors in the current market environment, aiming to bolster shareholder confidence and attract further investment.
- Earnings Beat: HealthStream reports a non-GAAP EPS of $0.18, beating expectations by $0.01, with revenue of $79.7 million exceeding forecasts by $3.49 million, showcasing the company's competitive edge and sustained profitability.
- Acquisition Strategy: HealthStream's acquisition of MissionCare Collective for up to $40 million aims to drive future growth by expanding service offerings and enhancing market share, further solidifying its position in the healthcare sector.
See More
HealthStream Q4 Earnings Beat Expectations with Strategic Acquisitions
- Strong Earnings Report: HealthStream reported a Q4 non-GAAP EPS of $0.18, beating expectations by $0.01, with revenue of $79.7 million reflecting a 7.4% year-over-year increase, surpassing estimates by $3.49 million, indicating robust market performance.
- Strategic Acquisitions: The company completed acquisitions of Virsys12 and MissionCare Collective for up to $40 million, aimed at enhancing service capabilities and competitive positioning through resource integration.
- Share Repurchase Program: HealthStream authorized a share repurchase program to buy back up to $10 million of common stock by November 11, 2025, having already repurchased $5 million in Q4, with another $5 million planned for January 2026, aimed at enhancing shareholder value.
- Full-Year Performance Overview: Total revenues for 2025 reached $304.1 million, up 4.3%, although operating income fell 4.9% to $20.2 million, primarily impacted by the CEO stock gift; excluding this, non-GAAP operating income was $24 million, reflecting a 12.8% increase, indicating improved profitability on an adjusted basis.
See More
HealthStream Reports Decline in Q4 Profit
- Profit Decline: HealthStream, Inc. reported a net profit of $2.53 million for Q4, translating to $0.09 per share, which is a significant drop from last year's $4.88 million and $0.16 per share, indicating pressure on the company's profitability.
- Adjusted Earnings: Excluding items, HealthStream's adjusted earnings stood at $5.35 million or $0.18 per share, showing some improvement in adjusted metrics, yet overall profitability remains below last year's levels.
- Revenue Growth: The company experienced a 7.4% year-over-year revenue increase, reaching $79.70 million compared to $74.23 million last year, suggesting some growth potential in its operations.
- Market Reaction: Despite revenue growth, the significant decline in profits may negatively impact investor confidence, leading to stock price volatility and reflecting market concerns regarding the company's future profitability.
See More
HealthStream Reports Q4 and Full-Year 2025 Financial Results
- Revenue Growth: HealthStream's Q4 2025 revenue reached $79.7 million, a 7.4% increase year-over-year, with subscription revenue rising by $5.8 million, indicating strong customer demand and reinforcing its market position in healthcare technology.
- Impact of CEO Stock Gift: The $3.8 million stock gift from CEO Frist led to a 48.8% decline in operating income to $2.4 million for Q4, but excluding this impact, non-GAAP operating income rose 31.7% to $6.2 million, showcasing the company's underlying growth potential.
- Annual Performance Review: For the full year 2025, revenues totaled $304.1 million, up 4.3%, although net income fell to $18.3 million; however, excluding the CEO stock gift's impact, non-GAAP net income increased by 5.8% to $21.2 million, reflecting effective cost control and efficiency improvements.
- Future Outlook: The company projects 2026 revenues between $323 million and $330 million, with net income expected to be between $20.4 million and $22.8 million, reflecting optimism about new sales and renewals while indicating HealthStream's pivotal role in the AI-driven healthcare landscape.
See More
Investment Opportunities in Oversold Healthcare Stocks
- Oversold Stocks Overview: The healthcare sector's oversold stocks present investors with opportunities to buy undervalued companies, particularly those with a Relative Strength Index (RSI) below 30, indicating potential short-term rebounds.
- Schrödinger Inc Performance: Schrödinger (NASDAQ:SDGR) has seen its stock price fall approximately 28% over the past month, currently holding an RSI of 29.9 and a 52-week low of $11.15, although shares rose 1.6% to $11.81 on Wednesday, indicating some rebound potential.
- Edge Stock Ratings: With a momentum score of 2.78, Schrödinger's performance is relatively weak in the market, yet its oversold status may attract investor interest, especially during market recoveries.
- Industry Dynamics Analysis: As the healthcare sector experiences volatility, investors should focus on the potential rebound opportunities of oversold stocks, particularly those with RSIs near or below 30, to capitalize on gains when the market stabilizes.
See More
